This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
== Career == In 1981, Valko joined the Hungarian Academy of Sciences, where she took on multiple roles, including heading the chromatography research group at the Central Research Institute for Chemistry of the Hungarian Academy of Sciences. Concurrently, she also served as a research scientist at the Institute of Enzymology from 1981 to 1985. Between 1993 and 1995, she worked as a senior research analytical chemist at Wellcome Research Laboratory. Subsequently, she held a position as a research investigator at GlaxoWellcome Medicines Research Centre from 1995 to 2000. From 2000 to 2015, she served as the senior research investigator at the Physicochemical Characterization Group at GlaxoSmithKline. In 2017, she founded Bio-Mimetic Chromatography and has been serving as its director since then. Later in 2019, she established Bio-Mimetic Cosmetics as a trading branch of Bio-Mimetic Chromatography. From 1977 to 1981, Valko served as a lecturer in the Department of Pharmaceutical Chemistry at Semmelweis University. Additionally, she held a Mappletorpe research fellowship in the School of Pharmacy at the University of London from 1991 to 1993. Since 2004, she has held the position of honorary professor at the University College London School of Pharmacy.
On 19 February, the chief of the United States Southern Command, General Francis L. Donovan, and senior Pentagon official Joseph Humire met with Delcy Rodríguez, Venezuelan defense minister Vladimir Padrino López and interior minister Diosdado Cabello in Caracas to discuss security. US Interior Secretary Doug Burgum visited Venezuela and met with Delcy Rodríguez on 4 March. They discussed the supply chains for critical minerals in Venezuela. On 5 March, the US State Department and Venezuelan authorities agreed to re-establish diplomatic and consular relations. On 12 March, the United States declared in court that they recognized Delcy Rodríguez as the sole head of state of Venezuela. Two days later, the flag of the United States was raised for the first time in seven years at the Embassy of the United States, Caracas. On 30 March, the United States reopened its embassy in Venezuela, meaning resumption of US diplomatic operations in Venezuela. On 30 April, direct commercial flights between the United States and Venezuela were resumed after a seven-year suspension. On 22 September, President Donald Trump met with Venezuela's interim President Delcy Rodriguez in the opening of the 81st session of the UN General Assembly in New York.
== Subsidiaries == Following declining earnings in 1965, HVEC reorganized into profit centers and established three wholly owned subsidiaries to diversify beyond particle accelerators. After U.S. orders for new accelerators ceased in the early 1970s, HVEC transformed into a miniconglomerate with more than ten subsidiaries, and industrial products from these units accounted for 80 percent of company revenues by 1972.
3,114km of high-pressure petroleum and gas pipelines An inland accumulation facility at Jameson Park, Gauteng (TM2), with a capacity of 180Ml A tank farm in Tarlton, Gauteng, for storage and distribution via rail and road, with a capacity of 29Ml A coastal terminal at Island View in Durban, for continuously supplying jet fuel to O.R. Tambo International Airport The Transnet pipeline network transports over 80% of refined fuel products for use in the inland market, and over 70% of the jet fuel used at O.R. Tambo International Airport. Approximately three-quarters of South Africa's fuel imports flow through Island View Precinct, which forms part of the Port of Durban. The Precinct serves as the country's main fuel storage and supply hub. Data for Transnet's pipeline fuel logistics is in the table below.
Sources: en.wikipedia.org
P. phalangioides are carnivorous predators that feed on insects, other spiders, and other small invertebrates. Unlike many other spiders, who simply feed on prey that have gotten stuck in their webs, these spiders frequently venture out from their own webs to hunt other spiders resting in their respective webs and feed on them or their eggs. In times of low prey availability, both the males and females of the species will turn to cannibalism to meet their nutritional needs.
== Function == Nicotinamide phosphoribosyltransferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.
=== Etymology === Osteoarthritis is derived from the prefix osteo- (from Ancient Greek: ὀστέον, romanized: ostéon, lit. 'bone') combined with arthritis (from ἀρθρῖτῐς, arthrîtis, lit. ''of or in the joint''), which is itself derived from arthr- (from ἄρθρον, árthron, lit. ''joint, limb'') and -itis (from -ῖτις, -îtis, lit. ''pertaining to''), the latter suffix having come to be associated with inflammation. The -itis of osteoarthritis could be considered misleading as inflammation is not a conspicuous feature. Some clinicians refer to this condition as osteoarthrosis to signify the lack of inflammatory response, the suffix -osis (from -ωσις, -ōsis, lit. ''(abnormal) state, condition, or action'') simply referring to the pathosis itself.
Sources: en.wikipedia.org
== Peptide hormones == Kaufmann and Brown 2008 find the An. gambiae adipokinetic hormone (AKH) mobilizes carbohydrates but not lipids. Meanwhile AKH/Corazonin Peptide (ACP) does not mobilize (or inhibit mobilization) of either. Mugumbate et al., 2013 provides in solution and membrane bound structures from a nuclear magnetic resonance investigation.
=== Before 1873 === Prior to Japan adopting the Gregorian calendar, it used the lunisolar Japanese calendar. The first five years of the era correspond to the following date ranges in the Gregorian calendar:
== External links == "Amylase, Alpha", I.U.B.: 3.2.1.11,4-α-D-Glucan glucanohydrolase. "Amylase, Alpha", I.U.B.: 3.2.1.11,4-α-D-Glucan glucanohydrolase. Beta-amylase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Aminoacylation is the process of adding an aminoacyl group to a compound. It covalently links an amino acid to the CCA 3′ end of a tRNA molecule. Each tRNA is aminoacylated (or charged) with a specific amino acid by an aminoacyl tRNA synthetase. There is normally a single aminoacyl tRNA synthetase for each amino acid, despite the fact that there can be more than one tRNA, and more than one anticodon for an amino acid. Recognition of the appropriate tRNA by the synthetases is not mediated solely by the anticodon, and the acceptor stem often plays a prominent role. Reaction:
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.